UK Value-Based Pricing Proposals Aim To Increase Access, Broaden Assessment of Drug Benefits
This article was originally published in The Pink Sheet Daily
Executive SummaryAn outline of the proposed overhaul to U.K. drug pricing and evaluation post-2013 is out for consultation until March 2011.
You may also be interested in...
Prices may decrease, but at least wider societal benefits are to be included in NICE’s assessment in the U.K.’s new value-based pricing (VBP) scheme for new pharmaceuticals, a change long demanded by critics of the health technology assessment body.
With eighteen months until the start of a new drug pricing scheme, the slow progress and lack of detail on the U.K.'s value-based pricing (VBP) approach worries industry and suggests transitional arrangements may be necessary.
The U.K.’s Health and Social Care Bill is struggling in parliament, but even if it falls, the government’s plans for value-based drug pricing may survive.